Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysis
- 23 January 2025
- journal article
- review article
- Published by Elsevier in Vascular Pharmacology
- Vol. 158, 107465
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary interventionPlatelets, 2024
- Aspirin hypersensitivity: a practical guide for cardiologistsEuropean Heart Journal, 2024
- Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trialThe Lancet Neurology, 2023
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- The evolution of GRADE (part 3): A framework built on science or faith?Journal of Evaluation in Clinical Practice, 2018
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2017
- Interpreting trial sequential analysisTransfusion, 2016
- Antiplatelet therapies for the treatment of cardiovascular diseaseNature Reviews Drug Discovery, 2010
- A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery diseaseEuropean Heart Journal, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003